---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065373"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:50:20.848910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports FY 2022 net loss of $121.8M; nominates first development candidate PM359 for CGD

## Summary
- Q4 2022 net loss $39.3M; full-year net loss $121.8M vs $165.4M in 2021.
- Cash, short-term investments $293.9M as of Dec 31, 2022, sufficient into 2025.
- Nominated PM359 as first development candidate for chronic granulomatous disease; IND-enabling studies planned in 2023.
- Preclinical proof-of-concept data for Friedreich's ataxia, cystic fibrosis, Wilson's disease, and PASSIGE technology disclosed.
- October 2022 IPO raised $180.2M net proceeds from upsized offering at $17.00 per share.

## SEC filing metadata
- accession: 0001193125-23-065373
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/0001193125-23-065373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/d367061d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065373
- JSON: https://secwatch.observer/filing/0001193125-23-065373.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065373.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Net income: Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022
  - Result: reported results
  source text: Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/0001193125-23-065373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.